Lv61
1882 积分 2021-03-03 加入
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
19天前
已关闭
Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities
21天前
已完结
Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study
1个月前
已完结
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
1个月前
已完结
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
1个月前
已完结
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
1个月前
已完结
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
1个月前
已完结
A novel conditioning regimen incorporating low-dose cyclophosphamide and thiotepa for haploidentical hematopoietic stem cell transplantation in pediatric patients with severe aplastic anemia at high risk of cardiotoxicity
1个月前
已关闭
Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation
1个月前
已完结
The impact of donor‐specific anti‐HLA antibody levels on primary poor graft function and graft rejection in rituximab desensitized haploidentical stem cell transplantation
1个月前
已完结
皖公网安备34019202002308
